ReviewFrontiers in pharmacology2024

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI.

Jianghua Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.